_1782039619 1782039619 Jadoun Science Publishing Group India jadounscience@gmail.com Jadoun Science Publishing Group India Tropical Journal of Pharmaceutical and Life Sciences Trop. j. pharm. life sci. 2349-9818 06 21 2026 13 3 Sara Shireen Zama Muqeem Shaik Nawaz Hafsa Zaheer Mohd Naseer Ullah Background: End-stage renal disease (ESRD) and chronic kidney disease (CKD) are growing more common.Whereas hemodialysis (HD) is the most common kidney replacement therapy for individuals with diabetes, dyslipidemia, anemia, and bone mineral abnormalities. Objective:  The objective of this study were to asses prescribing patterns in stage 5 of chronic kidney disease patients undergoing Hemodialysis.  Method: This study was an observational retrospective cohort study, it was conducted at Owaisi hospital, between march and April 2026. All adults on chronic HD were included. All information was were collected from governmental electronic health record, and patients were asked to answer some questions when data was not found in the system. Result: During the study of 50 patients with Chronic Kidney Disease Stage V, patients were mostly found male, Having 62 percent and 38 Percent were female.The number of drugs per patient ranged from 2 to 15, with a mean of 7.74+SD. A lot of the patients were between 51 and 60 years old, which is 42 percent. Some patients were 41 to 50 years old, which is 26 percent and patients who were 61 to 70 years old which is 24 percent. The most commonly used drugs are Furosemide (80%), Sevelamer (60%), Sodium Bicarbonate (60%), Inj. Erythropoietin (20%), Inj. Sucrose (20%) and Pentaprazole (40%). When we looked at the patients in the study we found that high blood pressure was the common health problem that these patients had. In fact 76 percent of the patients had blood pressure. A lot of the patients were having 36 percent both blood pressure and diabetes. Some patients also had anemia, which's 16 percent and some had hypothyroidism, which is 4 percent. A few patients had artery disease, which is 2 percent. All of the patients we surveyed had more than one health problem, and the most common combination was high blood pressure and diabetes, which is Chronic Kidney Disease Stage V patients, with high blood pressure and diabetes. Conclusion: In addition to widespread polypharmacy—the majority of patients were taking six to nine medications, This study of 50 CKD Stage V patients showed a significant frequency of diabetes and hypertension as comorbidities. The results emphasise how difficult it is to manage end-stage renal disease (ESRD) and how effective medication therapy is necessary to minimize interactions and enhance results. The course of the disease may be slowed by early management of DM and HPT. 06 21 2026 27 41 https://creativecommons.org/licenses/by-nc/4.0 10.61280/tjpls.v13i3.273 https://informativejournals.com/journal/index.php/tjpls/article/view/273 Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021 Oct;100(4):S1–276. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020 Feb;395(10225):709–33 Neovius M, Jacobson SH, Eriksson JK, Elinder CG, Hylander B. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ Open. 2014 Feb;4(2):e004251. Aune D, Sun X, Nie J, Huang W, Liao B, Wang Y. Self-reported chronic kidney disease and the risk of all-cause and cause-specific mortality: outcome-wide association study of 54 causes of death in the National Health Interview Survey. BMC Nephrol. 2022 Dec;23(1):165. Pan American Health Organisation. The burden of kidney diseases in the Region of the Americas, 2000-2019 [Internet]. PAHO. 2021 [cited 2023 Jul 30]. Available from: https://www.paho.org/en/enlace/burden-kidney diseases#:~:text=The%20age%2Dstandardized%20death%20rate,15.6%20deaths%20per %20100%2C000%20population. Hashmi MF, Benjamin O, Lappin SL. End-Stage Renal Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Aug 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK499861/ National Multisectoral Strategic Plan for Prevention and Control of Non Communicable Diseases (NCDs) in Namibia 2017/18 – 2021/22 [Internet]. Directorate: Primary Health Care Services Division: Family Health; 2017 [cited 2021 Nov 14]. Available from: National Multisectoral Strategic Plan for Prevention and Control of Non-Communicable Diseases (NCDs) in Namibia 2017/18 – 2021/22 | WHO | Regional Office for Africa Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Pill Burden, Adherence, Hyperphosphatemia, and Quality of Li... : Clinical Journal of the American Society of Nephrology Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opinion on Drug Metabolism & Toxicology. Diversity in the erg27 Gene of Botrytis cinerea Field Isolates from Strawberry Defines Different Levels of Resistance to the Hydroxyanilide Fenhexamid Fan J, de Lannoy IAM. Pharmacokinetics. Biochemical Pharmacology. https://www.sciencedirect.com/science/article/pii/S0006295213005790 Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. (PDF) Pharmacokinetics and dosage adjustment in patients with renal dysfunction (ckd def) Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322(13):1294–1304. https://doi.org/10.1001/jama.2019.14745 Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med. 2006;354(10):997-999. doi:10.1056/NEJMp058318. Pharmacotherapy Handbook Wells BG, DiPiro JT, Schwinghammer TL, DiPiro CV. Chronic kidney disease. In: Pharmacotherapy Handbook. 8th ed. New York: McGraw-Hill Medical; 2012. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International. 2005 Jun;67(6):2089-2100. doi:10.1111/j.1523-1755.2005.00365.x. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-1252. doi:10.1016/S0140-6736(16)32064-5. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-272. doi:10.1016/S0140-6736(13)60687-X. Bonner A, Wellard S, Caltabiano M. Development of a preliminary conceptual model of the patient experience of chronic kidney disease: a targeted literature review and analysis. BMC Nephrology. 2021;22(1):233. http://doi.org/10.1186/s12882-021-02440-9 Provenzano M, Coppolino G, De Nicola L, et al. Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. Advances in Therapy. 2021;38(12):5606-5628. https://doi.org/10.1007/s12325-021-02006-z Webster AC, Nagler EV, Morton RL, Masson P. Management of chronic kidney disease. The Lancet. 2017;389(10075):1238-1252. https://doi.org/10.1016/S0140-6736(16)32064-5 Heart Fail Rev. 2024 Mar;29(2):465-478. doi: 10.1007/s10741-023-10376-5. Epub 2023 Dec 10.Echocardiographic manifestations in end-stage renal disease - PubMed Abbasi MA, Chertow GM, Hall YN. 2010 Jul 19:2010:2002.End-stage renal disease - PubMed. Am Fam Physician. 2021 Nov 1;104(5):493-499.End-Stage Renal Disease: Medical Management - PubMed Daebes A, Essa A. Fluid and electrolyte imbalance in renal imbalance: Volume 25, Issue 5, May 2024, Pages 31319.https://doi.org/10.1016/j.mpaic.2024.03.006 Kettritz. R, loffing J, Potassium homeostasis – Physiology and pharmacology in a clinical context, Volume 249, September 2023, 108489, https://doi.org/10.1016/j.pharmthera.2023.108489 Badura k, Janc J, Wasik J, Gnitecki S, Skwira S, Mlynarska E, Rysz J and Franczyk B, Anemia of Chronic Kidney Disease—A Narrative Review of Its Pathophysiology, Diagnosis, and Management, 2024, 12(6),1191; https://doi.org/10.3390/biomedicines12061191 Iain C. Macdougall, Anaemia in CKD—treatment standard, 2024, 39 , 770–777,https://doi.org/10.1093/ndt/gfad250 Van der Plas WY, Noltes ME, van Ginhoven TM, Kruijff S. Secondary and tertiary hyperparathyroidism: a narrative review. Scand J Surg. 2020;109(4):271-278. http://doi.org/10.1177/1457496919866015 Jat JA, Mal P, Kumar D. Renal osteodystrophy in end stage renal failure patients on maintenance haemodialysis. J Clin Exp Nephrol. 2016;1(4):25. http://doi.org/10.21767/2472-5056.100025 Ben-David E, Hull R, Banerjee D. Diabetes mellitus in dialysis and renal transplantation. Ther Adv Endocrinol Metab. 2021;12:20420188211048663. http://doi.org/10.1177/20420188211048663 Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial. 2010;23(2):148-156. http://doi.org/10.1111/j.1525-139X.2010.00701.x Kim IS, Kim S, Yoo TH, Kim JK. Diagnosis and treatment of hypertension in dialysis patients: a systematic review. Clin Hypertens. 2023;29:24. doi: http://doi.org/10.1186/s40885-023-00240-x Van Buren PN. Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis. Curr Cardiol Rep. 2016;18(12):125. doi: http://doi.org/10.1007/s11886-016-0805-y Nguyen DB, Shugart A, Lines C, et al. Hemodialysis-associated infections. Semin Dial. 2017;30(5):454-460. doi: http://doi.org/10.1111/sdi.12613 Li PKT, Chow KM. Infectious complications in dialysis—epidemiology and outcomes. Nat Rev Nephrol. 2012;8(2):77-88. doi: http://doi.org/10.1038/nrneph.2011.194 Rahul S, Simon S, Doddayya H, Mudgal SM. Study on prescription pattern of chronic kidney disease patients in a tertiary care teaching hospital: a retrospective study. Int J Pharm Pharm Res. 2024;30(1):389-399. Parameshwari K, et al. Assessment of prescription pattern in chronic kidney disease patients undergoing hemodialysis. Journal of Population Therapeutics and Clinical Pharmacology. 2025;32(8). DOI: 10.53555/qdrepc83 Palikhey A, Paudel S, Agrawal K, Shrestha L and Shrestha J.Prescription Pattern of Drugs in Hemodialysis Patients at a Tertiary Care Hospital. DOI:10.3126/jucms.v13i01.78035 Alam D R, Hasan R and Jahan F. Prescription pattern and common complications in maintenance hemodialysis patients. DOI: https://doi.org/10.33545/26646692.2024.v6.i1a.11. Khangia M and Chakravarty P. Prescribing pattern of drugs in chronic kidney disease patients undergoing maintenance hemodialysis in a tertiary care hospital, Assam. DOI:10.18203/2319-2003.ijbcp20253730